Aliases & Classifications for Peritoneum Cancer

MalaCards integrated aliases for Peritoneum Cancer:

Name: Peritoneum Cancer 12 15
Malignant Tumor of Peritoneum 73
Cancer of Peritoneum 12
Peritoneal Neoplasms 73
Peritoneal Neoplasm 12
Cancer, Peritoneal 40
Peritoneal Cancer 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1725
ICD10 33 C48.1
ICD9CM 35 158.8

Summaries for Peritoneum Cancer

Disease Ontology : 12 An organ system cancer that is located in the peritoneum.

MalaCards based summary : Peritoneum Cancer, also known as malignant tumor of peritoneum, is related to primary peritoneal carcinoma and peritoneal mesothelioma, and has symptoms including sister mary joseph's nodule An important gene associated with Peritoneum Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are DNA Double-Strand Break Repair and Homologous DNA Pairing and Strand Exchange. The drugs Avastin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include colon, kidney and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Peritoneum Cancer

Diseases related to Peritoneum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 32.1 BRCA1 BRCA2
2 peritoneal mesothelioma 31.8 BAP1 WT1
3 fallopian tube carcinoma 29.9 BRCA1 BRCA2
4 pleural cancer 29.5 BAP1 KRT5 WT1
5 ovarian cancer 29.5 BRCA1 BRCA2 KRT7 PALB2 RAD51D
6 ovarian cancer 1 28.9 BRCA1 BRCA2 KRT7 PAX8 WT1
7 hereditary site-specific ovarian cancer syndrome 10.3 BRCA1 BRCA2
8 breast reconstruction 10.3 BRCA1 BRCA2
9 tuberculous salpingitis 10.3 BRCA1 BRCA2
10 nosophobia 10.3 BRCA1 BRCA2
11 cancerophobia 10.3 BRCA1 BRCA2
12 breast-ovarian cancer, familial 1 10.3 BRCA1 BRCA2
13 fallopian tube adenocarcinoma 10.2 BRCA1 BRCA2
14 synchronous bilateral breast carcinoma 10.2 BRCA1 BRCA2
15 premature menopause 10.2 BRCA1 BRCA2
16 fallopian tube disease 10.2 BRCA1 BRCA2
17 breast giant fibroadenoma 10.2 BRCA2 WT1
18 ocular melanoma 10.2 BAP1 BRCA2
19 tracheoesophageal fistula 10.2 BRCA2 PALB2
20 tracheoesophageal fistula with or without esophageal atresia 10.2 BRCA2 PALB2
21 isolated tracheoesophageal fistula 10.2 BRCA2 PALB2
22 lynch syndrome i 10.2 BRCA1 BRCA2
23 mutagen sensitivity 10.2 BRCA1 BRCA2
24 peritoneal serous papillary adenocarcinoma 10.2 PTGER4 WT1
25 pancreatic neuroendocrine tumor 10.2 BRCA2 PALB2
26 fanconi anemia, complementation group q 10.2 BRCA1 BRCA2
27 malignant epithelial mesothelioma 10.2 PTGER4 WT1
28 peritoneal serous adenocarcinoma 10.2 PTGER4 WT1
29 combined thymoma 10.2 KRT5 PAX8
30 fanconi anemia, complementation group n 10.2 BRCA2 PALB2
31 pre-malignant neoplasm 10.1 BRCA1 BRCA2 KRT5
32 breast carcinoma in situ 10.1 BRCA1 BRCA2 KRT5
33 fanconi anemia, complementation group j 10.1 BRCA1 PALB2
34 ductal carcinoma in situ 10.1 BRCA1 BRCA2 KRT5
35 dysgerminoma of ovary 10.1 BRCA1 BRCA2 WT1
36 breast disease 10.1 BRCA1 BRCA2 KRT5
37 rete testis neoplasm 10.1 PAX8 PTGER4
38 bilateral breast cancer 10.1 BRCA1 BRCA2 PALB2
39 in situ carcinoma 10.1 BRCA1 KRT5
40 female breast cancer 10.1 BRCA1 BRCA2 PALB2
41 sebaceous adenocarcinoma 10.1 KRT5 PTGER4
42 endocrine gland cancer 10.1 BRCA1 BRCA2 PAX8
43 pancreas adenocarcinoma 10.1 BRCA1 BRCA2 PALB2
44 inverted transitional papilloma 10.0 KRT5 KRT7
45 clear cell adenofibroma 10.0 BRCA2 KRT7
46 balloon cell malignant melanoma 10.0 KRT5 KRT7
47 benign breast adenomyoepithelioma 10.0 KRT5 KRT7
48 breast adenomyoepithelioma 10.0 KRT5 KRT7
49 ceruminoma 10.0 KRT5 KRT7
50 ampulla of vater adenocarcinoma 10.0 BRCA2 KRT7

Comorbidity relations with Peritoneum Cancer via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Peritoneum Cancer:



Diseases related to Peritoneum Cancer

Symptoms & Phenotypes for Peritoneum Cancer

UMLS symptoms related to Peritoneum Cancer:


sister mary joseph's nodule

GenomeRNAi Phenotypes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.48 ITPR3 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.48 ITPR3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.48 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.48 ITPR3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.48 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.48 BRCA1 ITPR3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.48 ITPR3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.48 WT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.48 ITPR3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.48 PAX8
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.48 BRCA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.48 ITPR3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.48 ITPR3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.48 BRCA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.48 ITPR3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.48 ITPR3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.48 ITPR3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.48 ITPR3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.48 ITPR3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.48 ITPR3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.48 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.48 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.48 PAX8
24 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.48 PAX8
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.48 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.48 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.48 PAX8
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.48 BRCA1 ITPR3 PAX8 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.48 WT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.48 BRCA1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.48 ITPR3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.48 BRCA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.48 ITPR3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.48 ITPR3 PAX8
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.48 WT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.48 PAX8
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.16 BRCA1
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.16 BRCA1
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.16 KRT5
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.16 KRT5
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.16 KRT5
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.16 KRT5
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.16 BRCA1
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.16 BRCA1
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.16 BRCA1
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.16 KRT7
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.16 BRCA1 KRT5 KRT7
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.16 KRT7
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.16 KRT5 KRT7
50 Decreased homologous recombination repair frequency GR00151-A-1 10.06 BRCA1

MGI Mouse Phenotypes related to Peritoneum Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 BAP1 BRCA1 BRCA2 KRT7 PALB2 PAX8
2 growth/size/body region MP:0005378 10.11 BAP1 BRCA1 BRCA2 ITPR3 KRT5 PALB2
3 homeostasis/metabolism MP:0005376 10.09 BAP1 BRCA1 BRCA2 ITPR3 KRT7 PAX8
4 behavior/neurological MP:0005386 10.08 BRCA1 BRCA2 ITPR3 KRT5 PALB2 PAX8
5 cardiovascular system MP:0005385 10.07 BAP1 BRCA1 PALB2 PAX8 PTGER4 RAD51D
6 embryo MP:0005380 10.04 BAP1 BRCA1 BRCA2 PALB2 PAX8 RAD51D
7 mortality/aging MP:0010768 10.02 BAP1 BRCA1 BRCA2 ITPR3 KRT5 PALB2
8 endocrine/exocrine gland MP:0005379 9.95 BAP1 BRCA1 BRCA2 ITPR3 PAX8 WT1
9 integument MP:0010771 9.95 BAP1 BRCA1 BRCA2 ITPR3 KRT5 PALB2
10 limbs/digits/tail MP:0005371 9.91 BRCA1 BRCA2 ITPR3 KRT5 PALB2 PAX8
11 neoplasm MP:0002006 9.73 BAP1 BRCA1 BRCA2 PALB2 PTGER4 WT1
12 no phenotypic analysis MP:0003012 9.55 BAP1 ITPR3 KRT5 PAX8 WT1
13 normal MP:0002873 9.43 BRCA1 BRCA2 ITPR3 PAX8 PTGER4 WT1
14 reproductive system MP:0005389 9.1 BAP1 BRCA1 BRCA2 ITPR3 PAX8 WT1

Drugs & Therapeutics for Peritoneum Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Avastin 18 49 BEVACIZUMAB Genentech July 2009

Drugs for Peritoneum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
3 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
17
Mechlorethamine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 51-75-2 4033
18
Ifosfamide Approved Phase 2, Phase 3,Phase 3 3778-73-2 3690
19
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
20
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
21
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
24
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
25
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
26
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
27
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
28
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
29
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
30
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
31
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
32
Epirubicin Approved Phase 3 56420-45-2 41867
33
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Niraparib Approved, Investigational Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
36
Trastuzumab Approved, Investigational Phase 3,Phase 1 180288-69-1 9903
37
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
38
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
39
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
40
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
41
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
42
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
43
Adenosine Approved, Investigational Phase 3,Phase 2 58-61-7 60961
44 Talazoparib Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 1207456-01-6
45
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
46
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
50
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Early Phase 1 56-86-0 33032

Interventional clinical trials:

(show top 50) (show all 718)
# Name Status NCT ID Phase Drugs
1 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
2 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
3 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
4 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
5 Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
6 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
7 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
8 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
9 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
10 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
11 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
12 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
13 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
14 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
15 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
16 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
17 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
18 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
19 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
20 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
21 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
22 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
23 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
24 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
25 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
26 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
27 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
28 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
29 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed NCT00976911 Phase 3 bevacizumab [Avastin];liposomal doxorubicin;paclitaxel;topotecan
30 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
31 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
32 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
33 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
34 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
35 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
36 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
37 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
38 Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer Completed NCT00769405 Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
39 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
40 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
41 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
42 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
43 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
44 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
46 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
47 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
48 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
49 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
50 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride

Search NIH Clinical Center for Peritoneum Cancer

Genetic Tests for Peritoneum Cancer

Anatomical Context for Peritoneum Cancer

MalaCards organs/tissues related to Peritoneum Cancer:

41
Colon, Kidney, Liver, Ovary, Prostate, Testis, Thymus

Publications for Peritoneum Cancer

Articles related to Peritoneum Cancer:

# Title Authors Year
1
Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. ( 19361840 )
2009

Variations for Peritoneum Cancer

Expression for Peritoneum Cancer

Search GEO for disease gene expression data for Peritoneum Cancer.

Pathways for Peritoneum Cancer

GO Terms for Peritoneum Cancer

Cellular components related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.65 BAP1 BRCA1 BRCA2 ITPR3 KRT5 KRT7
2 nucleoplasm GO:0005654 9.23 BAP1 BRCA1 BRCA2 ITPR3 PALB2 PAX8
3 lateral element GO:0000800 9.16 BRCA1 BRCA2

Biological processes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.81 BRCA1 BRCA2 PAX8 WT1
2 cellular response to DNA damage stimulus GO:0006974 9.78 BRCA1 BRCA2 PALB2 RAD51D
3 DNA repair GO:0006281 9.73 BRCA1 BRCA2 PALB2 RAD51D
4 chromosome organization GO:0051276 9.49 BRCA2 RAD51D
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.46 BRCA1 BRCA2
6 inner cell mass cell proliferation GO:0001833 9.4 BRCA2 PALB2
7 cellular response to gonadotropin stimulus GO:0071371 9.37 PAX8 WT1
8 metanephric epithelium development GO:0072207 9.32 PAX8 WT1
9 metanephric S-shaped body morphogenesis GO:0072284 9.26 PAX8 WT1
10 DNA recombination GO:0006310 9.26 BRCA1 BRCA2 PALB2 RAD51D
11 chordate embryonic development GO:0043009 9.16 BRCA1 BRCA2
12 double-strand break repair via homologous recombination GO:0000724 8.92 BRCA1 BRCA2 PALB2 RAD51D

Molecular functions related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.73 BRCA1 BRCA2 PALB2 PAX8 RAD51D WT1
2 protein binding GO:0005515 9.36 BAP1 BRCA1 BRCA2 ITPR3 KRT5 KRT7
3 transcription regulatory region DNA binding GO:0044212 9.33 BRCA1 PAX8 WT1
4 gamma-tubulin binding GO:0043015 8.96 BRCA2 RAD51D

Sources for Peritoneum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....